Cleanzine: your weekly cleaning and hygiene industry newsletter 18th April 2024 Issue no. 1110

Your industry news - first

The original and best - for over 20 years!

We strongly recommend viewing Cleanzine full size in your web browser. Click our masthead above to visit our website version.

Eurofins expands into hygiene testing in hospitals with acquisition of Biotech-Germande

Eurofins Scientific (EUFI.PA), global specialist in the bioanalytical testing of food, pharmaceuticals and the environment, has announced that it has signed an agreement to acquire Biotech-Germande SAS, one of the leading players in the environmental clinical testing and hospital hygiene market, as well as in medical device evaluation in France.

Located in Marseille, BG employs 40 staff and has established a strong reputation over the last 15 years in the testing of water, air, surfaces and endoscopes in hospitals and healthcare facilities, as well as evaluation of medical devices for manufacturers.

BG has seen, and expects to continue to post, strong growth - driven primarily by hospitals outsourcing mandatory infection controls, and increasingly stringent regulations for independent testing of medical devices.

The acquisition complements Eurofins' growing footprint in the testing market for the healthcare sector in France, and allows the Group to create a more compelling portfolio of services for hospitals and other healthcare facilities served by Bioaccess and Biomnis. In return, BG should gain access to Eurofins' infrastructure, including the Group's complete testing portfolio for hospitals and drug & medical device manufacturers, and could leverage Eurofins' extensive network to further accelerate growth. Eurofins' existing footprint in water testing, as well as the Group's respected capabilities in microbiology, should allow BG to expand its market reach or accelerate share gains in its existing markets.

"Biotech-Germande strengthens Eurofins' service offering to hospitals in a key area for patients' safety, and reinforces our growing footprint in medical device testing," says Dr Gilles Martin, Eurofins CEO. "We look forward to strengthening BG's position in its market by providing access to the Group's complete range of capabilities, as well as its client base."

"Biotech-Germande strengthens Eurofins' service offering to hospitals in a key area for patients' safety, and reinforces our growing footprint in medical device testing. We look forward to strengthening BG's position in its market by providing them access to the Group's complete range of capabilities, as well as client base."

With 20,000 staff in around 200 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

T: +32-2-766 1620
E: [email protected]
www.eurofins.com

17th December 2015